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Abstract
Aims/hypothesis Tobacco smoking, a risk factor for diabetes,
is an established modifier of DNA methylation. We
hypothesised that tobacco smoking modifies DNA methyla-
tion of genes previously identified for diabetes.
Methods We annotated CpG sites available on the Illumina
Human Methylation 450K array to diabetes genes previously
identified by genome-wide association studies (GWAS), and
investigated them for an association with smoking by compar-
ing current to never smokers. The discovery study consisted of
630 individuals (Bonferroni-corrected p=1.4×10−5), and we
sought replication in an independent sample of 674 individ-
uals. The replicated sites were tested for association with
nearby genetic variants and gene expression and fasting glu-
cose and insulin levels.
Results We annotated 3,620 CpG sites to the genes identified
in the GWAS on type 2 diabetes. Comparing current smokers
to never smokers, we found 12 differentially methylated CpG
sites, of which five replicated: cg23161492 within ANPEP
(p=1.3 ×10−12); cg26963277 (p=1.2× 10−9), cg01744331
(p = 8.0 × 10−6) and cg16556677 (p = 1.2 × 10−5) within
KCNQ1 and cg03450842 (p=3.1×10−8) within ZMIZ1. The
effect of smoking on DNA methylation at the replicated CpG
sites attenuated after smoking cessation. Increased DNA
methylation at cg23161492 was associated with decreased
gene expression levels of ANPEP (p=8.9×10−5). rs231356-
T, which was associated with hypomethylation of
cg26963277 (KCNQ1), was associated with a higher odds of
diabetes (OR 1.06, p=1.3×10−5). Additionally, hypomethy-
lation of cg26963277 was associated with lower fasting insu-
lin levels (p=0.04).
Conclusions/interpretation Tobacco smoking is associated
with differential DNA methylation of the diabetes risk genes
ANPEP, KCNQ1 and ZMIZ1. Our study highlights potential
biological mechanisms connecting tobacco smoking to excess
risk of type 2 diabetes.
Keywords DNAmethylation . Gene expression . Tobacco
smoking . Type 2 diabetes
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Introduction
In the last decade, genome-wide association studies (GWAS)
have been conducted in order to identify DNA sequence var-
iants for a wide range of diseases including type 2 diabetes
[1–3]. These GWAS have successfully identified numerous
single-nucleotide polymorphisms (SNPs) located in and near
genes that may be key in the development of type 2 diabetes.
Up to now, a total number of 88 genetic loci have been iden-
tified for type 2 diabetes [4].
Tobacco smoking is associated with an increased risk of
type 2 diabetes [5]. Several biological mechanisms have been
proposed through which smoking may have an effect on the
development of diabetes, including inflammation and the ef-
fect of nicotine on insulin resistance [6]. However, the exact
molecular mechanisms connecting smoking to an increased
risk of diabetes remain largely unknown. Previous research
has established that tobacco smoking has an important role
in DNAmethylation, the epigenetic mechanism of attachment
of a methyl group to a nucleotide [7–9]. DNAmethylation has
several functions in the human genome including the regula-
tion of gene expression and maintenance of genome stability
[10]. In line with this, previous studies have suggested DNA
methylation as a potential pathway in the association between
tobacco smoking and an increased risk of diabetes [11].
We hypothesised that tobacco smoking changes DNA
methylation of susceptibility loci identified in GWAS for type
2 diabetes. We therefore investigated the association between
DNA methylation in whole blood at loci identified for type 2
diabetes through GWAS and current tobacco smoking in a
Dutch population-based cohort study. Furthermore, we inves-
tigated the potential effect of DNAmethylation on the expres-
sion of genes near to the identified methylation sites.
Methods
Study population The study was conducted using data from
the Rotterdam Study; the design of the Rotterdam Study has
been described elsewhere [12]. In brief, in 1990 all inhabitants
living in the neighbourhood of Ommoord in Rotterdam, the
Netherlands, aged 55 years and over, were invited to partici-
pate (RS-1). In 2000, the cohort was extended with 3,011
participants who had reached the age of 55 years or who were
aged 55 years and over and had moved into the research area
(RS-2). In 2006, a third cohort of 3,934 participants aged
45 years and older was initiated (RS-3). The discovery panel
consisted of 630 non-diabetic participants in the first visit of
RS-3 (diabetes was def ined as a serum glucose
level≥7.0 mmol/l or the use of glucose-lowering medication)
of a random subset of 747 individuals of European descent
with DNA methylation data available. We sought replication
of the identified CpG sites in a set of 674 non-diabetic
participants from the third visit of RS-2 and the second visit
of RS-3. The individuals in the replication study did not par-
ticipate in the discovery study. The Rotterdam Study has been
approved by the medical ethics committee according to the
Population Screening Act: Rotterdam Study, executed by the
Ministry of Health, Welfare and Sports of the Netherlands. All
participants in the present analysis provided written informed
consent to participate and to obtain information from their
treating physicians.
Data collection Data on tobacco smoking was collected dur-
ing home interviews. Participants were asked about past and
present cigarette, cigar and pipe smoking behaviour and were
then categorised into current, former and never tobacco
smokers. We asked current smokers about the age at which
they started smoking and the number of cigarettes that they
smoked per day. Former smokers were asked at what age they
ceased smoking. Five of the participants had missing smoking
status and were therefore excluded from any analysis. During
the visit to the centre, weight and height were measured with
the participant in standing position and wearing normal
clothes. BMI was calculated as height in metres by weight in
kilograms squared. All participants had blood samples taken
during the visit to quantify DNA methylation, messenger
RNA (mRNA) expression levels, DNA sequence variants
and other blood measurements.
DNA methylation data DNAwas extracted from whole pe-
ripheral blood (stored in EDTA tubes) by standardised salting
out methods. Genome-wide DNA methylation levels were
measured using the Illumina Human Methylation 450K array
[13] (Illumina, San Diego, CA, USA). In short, samples
(500 ng of DNA per sample) were first treated with bisulfite
using the Zymo EZ-96 DNA-methylation kit (Zymo
Research, Irvine, CA, USA). Next, samples were hybridised
to the arrays according to the manufacturers’ protocols. The
methylation percentage of a CpG site was reported as a β
value ranging between 0 (no methylation) and 1 (full methyl-
ation). Processing of the Rotterdam Study DNA methylation
samples was performed at the Genetic Laboratory of Internal
Medicine, Erasmus University Medical Centre, Rotterdam.
Quality control of the samples was carried out using
Genome Studio (v2011.1, methylation module version 1.9.0;
Illumina). In the discovery panel, a total number of 16 samples
were removed: seven had a sample call rate below 99%; five
had incomplete bisulfite conversion and four had sex changes.
In the replication set, all samples passed the quality control
based on the first two principal components obtained using
principal component analysis (PCA), and no sex swaps were
detected. Further quality control of the probes was done based
on the detection p value calculated with Genome Studio.
Probes with a detection p value of more than 0.01 in more
than 1% of the samples were excluded. Additionally, sample-
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level quality control was performed using MethylAid (https://
bioconductor.org/packages/release/bioc/html/MethylAid.
html) [14]. This resulted in a total set of 474,528 probes that
were normalised using the Dasen option of the WateRmelon
R-package (https://www.bioconductor.org/packages/release/
bioc/html/wateRmelon.html) [15].
mRNA expression data Whole blood was collected
(PAXGene Tubes; Becton Dickinson, Erembodegem,
Belgium) and total RNA was isolated (PAXGene Blood
RNA kits; Qiagen, Venlo, the Netherlands). To ensure the
constant high quality of the RNA preparations, all RNA sam-
ples were analysed using the Labchip GX (Caliper,
Hopkinton, MA, USA) according to the manufacturer’s in-
structions. Samples with an RNA quality score of more than
7 were amplified and labelled (TotalPrep RNA; Ambion,
Austin, TX, USA) and hybridised to the Illumina
HumanHT12v4 Expression Beadchips (Illumina) as described
by the manufacturer’s protocol. Processing of the Rotterdam
Study RNA samples was performed at the Genetic Laboratory
of Internal Medicine, Erasmus University Medical Centre,
Rotterdam. The RS-3 expression dataset is available at GEO
(Gene Expression Omnibus) public repository under the ac-
cession GSE33828: 881 samples are available for analysis.
Illumina gene expression data was quantile-normalised to
the median distribution and subsequently log2-transformed.
The probe and sample means were centred to zero. Genes
were declared significantly expressed when the detection
p values calculated by GenomeStudio were less than 0.05 in
more than 10% of all discovery samples, which added to a
total number of 21,238 probes. Quality control was carried out
using the eQTL-mapping pipeline (https://github.com/
molgenis/systemsgenetics/tree/master/eqtl-mapping-pipeline)
[16]. We only analysed probes that uniquely mapped to the
human genome build 37 and represented gene mRNA
expression [17].
Selection of methylation sites A recent review summarising
findings from all diabetes GWAS was used to compile a list of
variants significantly associated with diabetes (88 variants)
[4]. Next, the list of 88 variants was extended with polymor-
phisms in linkage disequilibrium (R2 >0.8) in the HapMap
panel and within 500 kb using the SNAP Proxy Search tool
(https://broadinstitute.org/mpg/snap/ldsearch.php; accessed 1
October 2015). The final list included 890 SNPs, which were
tested for in-gene variants and effects on expression of a gene
within 1 Mb as found in a large publically available blood cis-
expression-quantitative trait loci (cis-eQTL) database (false
discovery rate [FDR] <0.05) [16]. We identified 525 SNPs
that were in-gene (mapping to 72 unique genes) and 316
SNPs with an eQTL effect (mapping to 50 unique genes).
The final number of unique genes was 111. The methylation
probes within and near these diabetes-related genes as
provided by Illumina were included in the analysis. We ex-
cluded probes from the Infinium HD methylation SNP list
with a minor allele frequency above 1% as provided by
Illumina, since variations in these SNPs can cause bias in
the methylation measurement [18]. We further excluded
known cross-reactive probes, since they can introduce bias
in the results [19]. In total, we included 3,620 CpG sites in
the analyses.
Statistical analysis The characteristics of the discovery and
replication populations were compared between current and
never smokers using IBM SPSS Statistics version 21.0.0.1
(IBM, Armonk, NY, USA). The p values were calculated
using independent sample t tests for continuous variables
and χ2-square tests for dichotomous variables.
The 3,620methylation probeswere tested for associationwith
tobacco smoking using a linear mixed model with the LME4
package in R version 3.1.0 with Dasen-normalised β values of
the CpG sites as outcome measure (https://cran.r-project.org/
web/packages/lme4/index.html) [20]. Extreme outliers (>4 SD
from the mean and >4SD from the before last) in the DNA
methylation values were excluded. We first compared current
smokers with never smokers and then performed a sensitivity
analysis on the identified CpG sites comparing former smokers
with never smokers. Covariates were selected based on known
association with DNAmethylation. The selected covariates with
fixed effects were age, sex and BMI [21–24]. Houseman-
estimated white blood cell proportions were used as fixed effects
to correct for cell mixture distribution [25]. Array number and
position on array were added in the model as covariates with
random effects to correct for batch effects. We corrected for
multiple testing using a robust Bonferroni-corrected p value of
1.4×10−5 as the threshold for significance (0.05 / 3,620 probes).
The probes identified in the discovery analysis were tested
for replication in the independent samples from the Rotterdam
Study. We used identical models with the addition of cohort
(RS-2 or RS-3) as a variable in the model to adjust for a
potential cohort effect. A Bonferroni-corrected p value of
0.05 divided by the number of significant findings in the dis-
covery study was used as a threshold of significant replication.
The replicated probes were further tested with total pack-
years in the current smokers to test the association between
tobacco smoking and cumulative exposure to smoking. We
further investigated the association between the replicated
probes and time since cessation in former smokers to study
the change in methylation after smoking cessation. To de-
crease the possibility of confounding in our association, we
further adjusted the model in a second analysis for other pos-
sible confounders and mediators. This analysis included total
cholesterol, HDL-cholesterol, triacylglycerol levels (natural
log-transformed), systolic blood pressure, daily alcohol intake
and C-reactive protein levels (natural log-transformed).
1000 Diabetologia (2016) 59:998–1006
Functional analysis Since DNA methylation may have an
effect on gene expression, we tested the association between
DNA methylation and mRNA expression levels of nearby
genes (cis) within 500 kb of the replicated CpG sites
(250 kb upstream and downstream of the CpG location).
First, residuals for mRNA expression were created after
regressing out the measured cell counts (granulocytes, lym-
phocytes, monocytes, platelets and erythrocytes), fasting state,
RNA quality score, plate number, age and sex on the mRNA
expression levels using a linear mixed model. We then created
residuals for DNA methylation regressing out the measured
white blood cells, age, sex, array number and position on array
on the Dasen-normalised β values of the CpG sites using a
linear mixed model. The residuals of the mRNA expression
levels and the residuals of the Dasen-normalised β values of
the CpG sites were tested for association using a linear regres-
sion model.
We also studied the association between the replicated CpG
sites and serum measures of fasting glucose and insulin com-
bining both the discovery and replication samples. Serum glu-
cose and insulin were measured using standard laboratory
techniques. The models were adjusted for the same covariates
as in the main analyses, with the addition of smoking category.
Serum insulin was natural log-transformed. A Bonferroni-
corrected p value for five tests was used. Furthermore, we
searched for genetic variants (methylation quantitative trait
loci [met-QTLs]) associated with the replicated methylation
sites in the publicly available data from the paper by
Grundberg et al [26]. Significant met-QTLs were then tested
for an association with type 2 diabetes in the publicly available
data from the DIAGRAM consortium, using a Bonferroni-
corrected p value of 0.01 (0.05 / 5 met-QTLs) [3].
Results
A total of 630 participants were included in the discovery
study. Clinical characteristics of the study population by
smoking category are listed in Table 1. The participants were
on average 59.5±8.0 years old and 45% were men. The sam-
ples consisted of 175 current smokers, 184 never smokers and
271 former smokers. On average, current smokers had lower
HDL-cholesterol, higher triacylglycerol and serum C-reactive
protein than never smokers. Also alcohol consumption was
higher in current smokers than in former smokers or never
smokers. In the replication population, 68 individuals were
current smokers, 238 were never smokers and 368 were for-
mer smokers. Clinical characteristics of the replication popu-
lation can be found in electronic supplementary material
(ESM) Table 1.
After correction for multiple testing (p=1.4×10−5), we
identified 12 differentially methylated CpG sites when com-
paring current smokers to never smokers in the discovery
study (Table 2; results for all probes are presented in ESM
Table 2). The 12 differentially methylated CpG sites were
located within eight genes. The most significant finding was
cg23161492 located within the gene ANPEP on chromosome
15 (p=1.3×10−12). On chromosome 11, four CpG sites locat-
ed within the gene KCNQ1 were significantly associated with
current tobacco smoking (cg26963277, p = 1.2 × 10−9;
cg13428066, p = 5.8 × 10−6; cg01744331, p = 8.0 × 10−6;
cg16556677, p=1.2×10−5). Within the gene ZMIZ1 on chro-
mosome 10, two CpG sites were significant differentially
methyla ted be tween current and never smokers
(cg03450842, p=3.1×10−8; cg21344746, p=6.6×10−6). In
addition, we identified CpG sites in and near INPP5E,
NDUFS5, FCHSD2, PBX4 and TCF19 that were differential-
ly methylated in current smokers compared with never
smokers.
We attempted replication of the 12 differentially methylat-
ed CpG sites from the discovery study in 674 independent
participants of the second and third cohort of the Rotterdam
Study. We used a p value of 4.2×10−3 (0.05 / 12) as a thresh-
old of significant replication. We significantly replicated the
five CpG sites cg23161492 (ANPEP), cg26963277 (KCNQ1),
cg03450842 (ZMIZ1) , cg01744331 (KCNQ1) and
cg16556677 (KCNQ1) (Table 2). Furthermore, the replicated
associations were robust to further adjustment for possible
confounders including systolic blood pressure, total cholester-
ol, HDL-cholesterol, triacylglycerol, alcohol consumption
and C-reactive protein (ESM Table 3). Boxplots of replicated
probe β values per smoking category are presented in Fig. 1.
When we adjusted the effect of the top signal within the
KCNQ1 gene (cg26963277) for the second (cg01744331) or
third (cg16556677) signal within KCNQ1, cg26963277 was
associated with current smoking, whereas cg01744331 and
cg16556677 did not show an association (p=0.84 and 0.35,
respectively).
To study the effect of smoking cessation on the replicated
CpG sites, we compared former smokers with never smokers
and tested the association between time since smoking cessa-
tion and DNAmethylation. DNAmethylation at the five CpG
sites were not differentially methylated when former smokers
were compared with never smokers (Table 3). Methylation at
cg23161492 (p= 2.6 × 10−6), cg26963277 (p= 2.1 × 10−4),
cg01744331 (p=5.1×10−5) and cg16556677 (p=1.2×10−3)
was associated with time since smoking cessation.
Additionally, methylation at the CpG sites cg23161492,
cg26963277, cg03450842 and cg01744331 was associated
with cumulative exposure to tobacco smoking.
In the 630 individuals from the discovery panel, six genes
out of 20 candidates were significantly expressed in the
analysed whole-blood samples. The 12 methylation expres-
sion combinations are shown in ESM Table 4. The p value
threshold for association was 4.2 × 10−3 (0.05/12 tests).
Increased methylation at cg23161492 was negatively
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associated with gene expression levels of ANPEP
(p=8.9×10−5) (ESM Fig. 1).
We observed a putative effect of the CpG site
cg26963277 with fasting serum insulin (effect: 0.004,
p= 0.04). Results for the associations between all repli-
cated CpG sites and serum fasting glucose and insulin
are presented in ESM Table 5.
We identified a significant met-QTL for all replicated CpG
sites, except cg0345084 (ESM Table 6). The T allele of the
SNP rs231356 was associated with lower methylation of both
cg26963277 and cg01744331 (KCNQ1). Also, the T allele of
the SNP rs231356 was associated with an increased odds of
type 2 diabetes (OR 1.06, p=1.3×10−5).
Discussion
Our findings suggest that tobacco smoking is associated with
differential methylation of CpG sites within the type 2 diabe-
tes risk genes ANPEP, KCNQ1 and ZMIZ1. The associations
were robust to adjustment for potential confounders and the
effect of tobacco smoking appeared to be reversible after
Table 1 Baseline characteristics
of the study population according
to smoking status
Characteristic Total Current Former Never p valuea
N 630 175 271 184
Age, years 59.5 ± 8.0 57.9 ± 6.6 60.9 ± 8.5 59.0 ± 8.1 0.16
Male sex (%) 283 (45) 85 (49) 126 (47) 72 (39) 0.07
BMI, kg/m2 27.4 ± 4.5 26.7 ± 4.4 27.6 ± 4.3 27.6 ± 4.8 0.07
Fasting glucose, mmol/l 5.35 ± 0.55 5.33± 0.58 5.40± 0.55 5.30± 0.52 0.65
Systolic blood pressure, mmHg 138.5 ± 63.0 136.4 ± 60.4 139.7 ± 67.4 138.7 ± 58.8 0.71
Diastolic blood pressure, mmHg 88.0 ± 65.0 86.0 ± 62.1 89.0 ± 9.8 88.4 ± 60.3 0.71
Total cholesterol, mmol/l 5.60 ± 1.03 5.60± 1.07 5.62± 1.01 5.56± 1.02 0.72
HDL-cholesterol, mmol/l 1.41 ± 0.40 1.34± 0.39 1.44± 0.41 1.44± 0.37 0.01
Triacylglycerol, mmol/l 1.45 ± 0.81 1.62± 1.02 1.39± 0.62 1.40± 0.81 0.02
C-reactive protein, mg/l 2.55 ± 4.74 3.17± 7.03 2.52± 3.54 2.03± 3.31 0.05
Alcohol consumption, g/day 18.3 ± 11.0 19.4 ± 12.7 19.0 ± 10.9 16.1 ± 9.3 0.006
Fastingb, yes (%) 628 (100) 173 (99) 271 (100) 184 (100) 0.15
Data are mean ± SD or n (%)
a Current vs never smokers
b The participants who provided blood after an overnight fast
Table 2 Significant associations between current vs never tobacco smoking and methylation of diabetes genes
CpG site Chromosome Position Hg19 Discovery Replication Gene
β SE p value β SE p value
cg23161492 15 90357202 −0.044 0.006 1.3 × 10−12 −0.045 0.006 3.4 × 10−11 ANPEP
cg26963277 11 2722407 −0.026 0.004 1.2 × 10−9 −0.034 0.004 3.3 × 10−14 KCNQ1
cg03450842 10 80834947 −0.017 0.003 3.1 × 10−8 −0.030 0.004 2.2 × 10−12 ZMIZ1
cg14024579 9 139332845 −0.022 0.004 1.1 × 10−7 −0.015 0.006 0.01 INPP5E
cg14656441 1 39500070 0.026 0.005 1.5 × 10−6 0.016 0.008 0.05 NDUFS5
cg13912027 11 72759293 0.022 0.005 2.1 × 10−6 −0.001 0.006 0.89 FCHSD2
cg00591868 19 19729048 −0.015 0.003 4.6 × 10−6 −0.003 0.005 0.51 PBX4
cg13428066 11 2677768 0.015 0.003 5.8 × 10−6 0.007 0.006 0.28 KCNQ1
cg21344746 10 80831230 0.016 0.004 6.6 × 10−6 0.001 0.005 0.82 ZMIZ1
cg16095155 6 31127863 −0.013 0.003 7.2 × 10−6 −0.007 0.004 0.12 TCF19
cg01744331 11 2722358 −0.013 0.003 8.0 × 10−6 −0.025 0.003 7.4 × 10−12 KCNQ1
cg16556677 11 2722401 −0.015 0.003 1.2 × 10−5 −0.027 0.004 3.9 × 10−10 KCNQ1
Adjusted for age, sex, BMI, Houseman-estimated white blood cell proportions and batch effects
Bonferroni-corrected threshold for significance: 0.05/3,620 = 1.4 × 10−5
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smoking cessation. In addition, methylation within ANPEP
was significantly associated with gene expression levels of
ANPEP. Methylation at KCNQ1 was associated with fasting
insulin levels and genetic data supported a role for methyla-
tion at KCNQ1 in the development of diabetes. This study
provides further insight into potential biological mechanisms
underlying the association between tobacco smoking and an
excess risk of type 2 diabetes.
In contrast to the findings for current vs never smokers, we
found similar DNA methylation levels at the replicated CpG
sites when comparing former smokers to never smokers.
Furthermore, four significant CpG sites were associated with
time since smoking cessation, suggesting a return after
smoking cessation to DNAmethylation levels similar to never
smokers. This is in agreement with previous studies investi-
gating the role of smoking cessation in DNA methylation [7,
27, 28]. DNA methylation may return to levels similar to
never smokers at some sites, while other sites stay differen-
tially methylated. Our results are in agreement with a potential
beneficial effect of smoking cessation on DNAmethylation at
risk loci for diabetes. Furthermore, at four CpG sites we ob-
served a dose-dependent effect of smoking underscoring the
importance of cumulative tobacco exposure over time.
We identified three CpG sites within intron 11 of KCNQ1
(potassium channel, voltage gated KQT-like subfamily Q,
member 1) that were differentially methylated in current
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Fig. 1 Boxplots depicting the
methylation values in the
replicated CpG sites (cg23161492
[a], cg26063277 [b], cg03450842
[c], cg01744331 [d], cg16556677
[e]) in current, former and never
smokers. The bold horizontal
lines represent the median
methylation values, the box
represents the interquartile range,
the whiskers extend to 1.5 times
the interquartile range or the most
extreme value, and the circles
represent a participant’s unique
methylation value
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smokers compared with never smokers. Previous studies have
reported differential DNA methylation at the KCNQ1 locus in
pancreatic islets and adipose tissue of diabetes cases and non-
diabetes controls [29, 30]. Adjustment analyses suggested that
cg26963277 is the driving CpG site associated with current
smoking at this locus. Furthermore, we found the met-QTL
(rs231356) for cg26963277 to be associated with the risk of
diabetes. More specifically, the T allele of rs231356 is associ-
ated with lower methylation of cg26963277 and an increased
odds of type 2 diabetes. In agreement with this observation,
tobacco smoking lowers methylation at cg26963277 and is
associated with an increased risk of diabetes .
Additionally, our data suggest an association between
cg26963277 and fasting insulin levels: increased meth-
ylation was putatively associated with increased fasting
insulin levels. Although we did not observe an associa-
tion between DNA methylation at cg26963277 and ex-
pression of KCNQ1, our results provide evidence that
smoking may increase the risk of diabetes through de-
creased methylation at KCNQ1 and a subsequent de-
crease in fasting insulin levels.
Further, current tobacco smoking was associated with a
4.4% decrease in methylation at cg23161492 located near
the 5′ untranslated region (UTR) ofANPEP and this decreased
methylation was correlated with increased gene expression
levels of ANPEP. ANPEP encodes the protein alanine amino-
peptidase, a widely expressed enzyme involved in various
cellular processes including cell proliferation, differentiation
and apoptosis [31]. The observation that current smoking,
which increases the risk of type 2 diabetes, may lead to higher
gene expression levels of ANPEP is in line with the observa-
tion of Locke and colleagues [32]. The risk allele of the SNP
rs2007084, identified by the DIAGRAM consortium, is
also associated with increased gene expression of
ANPEP in islet cells [32]. This suggests that increased
expression of ANPEP leads to an increased risk of type
2 diabetes. The observation that DNA sequence varia-
tion and DNA methylation at this locus is associated
with increased expression levels of ANPEP suggests a
role for ANPEP in the pathogenesis of type 2 diabetes,
rather than the gene AP3S2 proposed by prior GWAS
[3].
We further identified the CpG cg03450842, near the 5′
UTR of ZMIZ1, to be differentially methylated in smokers
compared with never smokers. The CpG cg03450842 has
been identified previously to be associated with smoking
[11]. Unfortunately, we had no expression data available in
our samples for this gene and could therefore not study the
effect of methylation at cg03450842 on gene expression of
ZMIZ1.
The strength of the current study is the large sample size
with available data on DNAmethylation, gene expression and
genetic variants, which allowed detailed investigation of the
interrelationship between tobacco smoking, DNAmethylation
and gene expression. A limitation of the current work is the
use of whole-blood samples for the quantification of DNA
methylation and gene expression. As both methylation and
expression may be tissue specific, we might have overlooked
potential associations between tobacco smoking and dif-
ferential methylation of diabetes-related genes in other
tissues (e.g. liver, fat, pancreas or muscle tissue).
Furthermore, observed associations may not be
generalisable to other tissues. Another limitation is the
challenge of gene annotation in GWAS. GWAS locate
DNA sequence variants for phenotypes, but the under-
lying causal gene might be difficult to designate. To
minimise this problem we limited our analysis to genes
annotated to in-gene variants and known cis-eQTL ef-
fects. Therefore the diabetes risk genes selected in our
study are more plausible as being the causal gene for
diabetes.
In summary, our study suggests an effect of tobacco
smoking on DNA methylation of the diabetes-related genes
ANPEP, KCNQ1 and ZMIZ1. Our study provides further in-
sight into potential mechanisms linking tobacco smoking to an
excess risk of type 2 diabetes.
Table 3 Association between CpG sites and former smokers compared with never smokers, time since smoking cessation and cumulative smoking
exposure in pack-years
CpG site Gene Former vs never smokers Cessation time Pack-years
β (SE) p value βa (SE) p value βa (SE) p value
cg23161492 ANPEP −0.007 (0.006) 0.24 0.014 (0.003) 2.6 × 10−6 −0.007 (0.002) 2.8 × 10−3
cg26963277 KCNQ1 −0.006 (0.003) 0.05 0.006 (0.002) 2.1 × 10−4 −0.006 (0.002) 9.0 × 10−4
cg03450842 ZMIZ1 −0.005 (0.002) 0.06 0.002 (0.001) 0.20 −0.003 (0.001) 1.6 × 10−3
cg01744331 KCNQ1 −0.003 (0.002) 0.21 0.005 (0.001) 5.1 × 10−5 −0.004 (0.001) 1.1 × 10−4
cg16556677 KCNQ1 −0.007 (0.003) 7.1 × 10−3 0.005 (0.001) 1.2 × 10−3 −0.003 (0.001) 0.05
Adjusted for age, sex, BMI, white blood cell counts and batch effects. Bonferroni corrected
aβ represents change in methylation per 10 years since smoking cessation and per 10 pack-years.
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